Anna E. Martinez

Prof. Anna E. Martinez


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2014 in BMC Medicine
Verified
Journal Article
Open access
PDF file
KGKenneth R Goldschneider
Kenneth R Goldschneider
JGJulie Good
Julie Good
EHEmily Harrop
Emily Harrop
Christina LiossiChristina Liossi
Christina Liossi
ALAnne Lynch-Jordan
Anne Lynch-Jordan
DSDanette Stanko-Lopp
Danette Stanko-Lopp
Inherited epidermolysis bullosa (EB) comprises a group of rare disorders that have multi-system effects and patients present with a number of both acute and chronic pain care needs. Effects on quality of life are substantial. Pain and itching are burdensome daily problems. Experience with, and knowledge of, the best pain and itch care for these patients is minimal. Evidence-based best care practice guidelines are needed to establish a base of knowledge and practice for practitioners of many disciplines to improve the quality of life for both adult and pediatric patients with EB. The process was begun at the request of Dystrophic Epidermolysis Bullosa Research Association International (DEBRA International), an organization dedicated to improvement of care, research and dissemination of knowledge for EB patients worldwide. An international panel of experts in pain and palliative care who have extensive experience caring for patients with EB was assembled. Literature was reviewed and systematically evaluated. For areas of care without direct evidence, clinically relevant literature was assessed, and rounds of consensus building were conducted. The process involved a face-to-face consensus meeting that involved a family representative and methodologist, as well as the panel of clinical experts. During development, EB family input was obtained and the document was reviewed by a wide variety of experts representing several disciplines related to the care of patients with EB. The first evidence-based care guidelines for the care of pain in EB were produced. The guidelines are clinically relevant for care of patients of all subtypes and ages, and apply to practitioners of all disciplines involved in the care of patients with EB. When the evidence suggests that the diagnosis or treatment of painful conditions differs between adults and children, it will be so noted. Evidence-based care guidelines are a means of standardizing optimal care for EB patients, whose disease is often times horrific in its effects on quality of life, and whose care is resource-intensive and difficult. The guideline development process also highlighted areas for research in order to improve further the evidence base for future care.

22 November 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
DKDimitra Kiritsi
Dimitra Kiritsi
KDKathrin Dieter
Kathrin Dieter
ENElke Niebergall-Roth
Elke Niebergall-Roth
SFSilvia Fluhr
Silvia Fluhr
CDCristina Daniele
Cristina Daniele
MKMark Andreas Kluth
Mark Andreas Kluth
BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating, and life-threatening inherited skin fragility disorder that comes about due to a lack of functional type VII collagen, for which no effective therapy exists. ABCB5 + dermal mesenchymal stem cells (ABCB5 + MSCs) possess immunomodulatory, inflammation-dampening, and tissue-healing capacities. In a Col7a1 –/– mouse model of RDEB, treatment with ABCB5 + MSCs markedly extended the animals’ lifespans. METHODS: In this international, multicentric, single-arm, phase I/IIa clinical trial, 16 patients (aged 4–36 years) enrolled into 4 age cohorts received 3 i.v. infusions of 2 × 10 6 ABCB5 + MSCs/kg on days 0, 17, and 35. Patients were followed up for 12 weeks regarding efficacy and 12 months regarding safety. RESULTS: At 12 weeks, statistically significant median (IQR) reductions in the Epidermolysis Bullosa Disease Activity and Scarring Index activity (EBDASI activity) score of 13.0% (2.9%–30%; P = 0.049) and the Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa clinician (iscorEB‑c) score of 18.2% (1.9%–39.8%; P = 0.037) were observed. Reductions in itch and pain numerical rating scale scores were greatest on day 35, amounting to 37.5% (0.0%–42.9%; P = 0.033) and 25.0% (–8.4% to 46.4%; P = 0.168), respectively. Three adverse events were considered related to the cell product: 1 mild lymphadenopathy and 2 hypersensitivity reactions. The latter 2 were serious but resolved without sequelae shortly after withdrawal of treatment. CONCLUSION: This trial demonstrates good tolerability, manageable safety, and potential efficacy of i.v. ABCB5 + MSCs as a readily available disease-modifying therapy for RDEB and provides a rationale for further clinical evaluation. TRIAL REGISTRATION: Clinicaltrials.gov NCT03529877; EudraCT 2018-001009-98. FUNDING: The trial was sponsored by RHEACELL GmbH & Co. KG. Contributions by NYF and MHF to this work were supported by the NIH/National Eye Institute (NEI) grants RO1EY025794 and R24EY028767.

11 June 2019 in Trials
Verified
Journal Article
Open access
PDF file
JKJohannes S. Kern
Johannes S. Kern
ASAgnes Schwieger-Briel
Agnes Schwieger-Briel
SLSandra Löwe
Sandra Löwe
MSMark Sumeray
Mark Sumeray
CDCharles Davis
Charles Davis
AMAnna E. Martinez
Anna E. Martinez
Epidermolysis bullosa (EB) is a group of rare, genetic diseases that affect the integrity of epithelial tissues, most notably the skin. Patients experience recurrent skin wounding, with severity depending on type, sub-type, and mutation. Oleogel-S10, a formulation of birch bark extract, has demonstrated efficacy in a Phase 2 trial assessing re-epithelialization of wounds in EB. EASE (NCT03068780, EudraCT 2016–002066-32) is a randomized, Phase 3, placebo-controlled study designed to determine the efficacy of Oleogel-S10 versus placebo in patients with EB. EASE is a Phase 3, two-phase study comprising a 90-day, double-blind, randomized, placebo-controlled phase, followed by 24 months of open-label, single-arm follow-up. Patients with junctional EB, dystrophic EB, or Kindler syndrome and target wounds (10 - 50cm2) present for > 21 days and < 9 months, are randomized in a 1:1 ratio to receive wound dressings according to local standard of care with or without Oleogel-S10. Placebo is based on the Oleogel-S10 vehicle, which is sunflower oil formulated to have a consistency indistinguishable from that of the active product. The primary endpoint of the trial, directed by the US health authority according to the required study endpoints for chronic cutaneous ulcer and burn wounds, is to compare the efficacy of Oleogel-S10 versus placebo according to the proportion of patients with complete closure of the target wound within 45 ± 7 days of treatment. Additional EB-focused endpoints include wound burden, patient-reported outcomes, and safety. Results of the primary endpoint are anticipated to be available by H2 2019. ClinicalTrials.gov, NCT03068780 . EudraCT, 2016–002066-32. Registered on 3 March 2017.

13 September 2021 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
CPChristine Prodinger
Christine Prodinger
SCSubhanitthaya Chottianchaiwat
Subhanitthaya Chottianchaiwat
JMJemima E. Mellerio
Jemima E. Mellerio
JMJohn A. McGrath
John A. McGrath
LOLinda Ozoemena
Linda Ozoemena
AMAnna E. Martinez
Anna E. Martinez

16 November 2017 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
RARosalind Ashton
Rosalind Ashton
JMJamil Moledina
Jamil Moledina
BSBranavan Sivakumar
Branavan Sivakumar
JMJemima E. Mellerio
Jemima E. Mellerio
AMAnna E. Martinez
Anna E. Martinez